Peptonic Medical's ongoing applications for the intimate wash and for the treatment of fungal infection has received positive statements from the international review
Peptonic Medical has previously announced that it applied for patents for the intimate wash and for the treatment of fungal infections, which have been accompanied by so-called PCT applications (Patent Cooperation Treaty). Both applications have now been reviewed by the international review authority, the outcome is that they recommend that patents be granted, as the patent applications meet the requirements for novelty, inventive step and industrial applicability. Now it remains to submit applications at the national level and get the applications granted there.
• The first applied for patent protection "intimate wash" to use our proprietary intimate wash which is cleansing, protective and moisture-preserving, refers to the Company's personal care product VagiVital ® Moisturizing V Cleanser. The background to this patent application is that we discovered the very positive properties of our proprietary Intimate Wash. Many of the competing products on the market today are both drying and have the wrong pH. Our product, which has been on the market since mid-2021, has received many positive reviews from users. The application was submitted in May 2020.
• The second applied for patent protection "fungal infection" to use a further developed variant of our vaginal gel for the treatment and prevention of fungal infections. A clinical study is underway to demonstrate this effect at Karolinska Hospital in Huddinge.
- "We are very happy about this news, that we have come one step closer to approval of the patent protection for our intimate wash and for the treatment/prevention of fungal infections. The PCT (Patent Cooperation Treaty) is an international patent system that enables companies to apply for patent protection internationally for their innovations in approximately 150 countries. Within the framework of the PCT, a preliminary assessment of patentability is made before the application proceeds to the national phase where national patent applications are submitted. Concretely, this means that you have a fairly good idea of the possibilities of obtaining patent protection for an innovation even before you submit the national patent applications," says Erik Sundquist, CEO, Peptonic Medical AB.
The next step for Peptonic Medical will be to decide in which countries the patents will be applied for, which will happen in the near future.
This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-11-2022 09:19 CET.
Erik Sundquist, CEO
Telefon: + 46 722 49 90 43
E-post: erik.sundquist@peptonicmedical.se
ABOUT Peptonic Medical AB
Peptonic Medical AB (publ) is an innovative medtech start up company, dedicated to researching and developing ground breaking products in the women’s health space and improving access to these products on a global scale.
Founded in 2009, the company now produces its own range of intimate health and wellness products under the Vagivital brand and is also the parent company of Lune Group Oy Ltd and Peptonic Medical Israel Ltd. The group is home to a holistic range of products that are trusted by experts and loved by customers. Peptonic Medical share has been traded on Spotlight (www.spotlightstockmarket.com) in Stockholm since 2014.